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Metabolic phenotyping, nowadays most often termed
‘metabolomics’, is becoming increasingly applied in mo-
lecular epidemiology, particularly in concert with gen-
omics. Since Jeremy Nicholson and colleagues coined the
term ‘metabonomics’ in 1999,1 over 15 000 publications
have appeared under this conceptual and technological
umbrella (a Pubmed search on 15 August 2016 at [http://
www.ncbi.nlm.nih.gov/pubmed/] with metabonomics or
metabolomics or lipidomics). Most of the published works
have been, and still continue to be, methodologically ori-
ented2 and thereby bear little direct relevance to applied
epidemiology. Particularly the spectroscopy-based chemo-
metric approaches–typically aiming at classification of in-
dividuals with or without a particular disease–have for a
long time (mis)guided metabolomics research.3–9 Many of
the limitations of these types of multivariate metabolomics
applications are currently well understood: overtraining of
classification models with high numbers of variables (typ-
ically spectral data points), cross-sectional study settings
with very small numbers of individuals and no independent
replication.5,7,8 However, some lack of clarity still remains,
partly related to some misplaced conceptions as to the
scope of truly personalized medicine.10–13 Individual diag-
nostics of polygenic diseases, when both the disease liabil-
ity14 and the metabolic phenotypes15–17 are continuous,
fundamentally preclude diagnostic models that would pro-
vide both high sensitivity and high specificity.4,5,7,18–20 For
example, conditions like autism, long considered rigid
disease classifications, clearly involve a somewhat arbi-
trary division of a continuously distributed underlying li-
ability,21 limiting attempts at improved binary
classification. In addition, many metabolomics applica-
tions have ignored confounding in data analyses and inter-
pretations, though it is well established in observational
epidemiology that confounding–by lifestyle and socioeco-
nomic factors, or by baseline health status, treatment and
medication effects–is prone to affect many
associations.22,23
Getting quantitative and molecular
Recent technological developments resulting in increased
numbers of quantitative molecular applications of metabo-
lomics triggered the idea for this themed issue in metabolic
phenotyping in epidemiology. The pivotal role of absolute
quantification of identified molecular entities in epidemi-
ology and genetics is evident from a multitude of recent ap-
plications.6,24–28 The data analysis protocols in mass
spectrometry (MS) often build on a quantitative logic, i.e.
identification, assignment and evaluation of specific mo-
lecular signals. Though most of the MS-based studies have
been small or moderate in numbers from the epidemiolo-
gical perspective, multiple interesting studies have recently
been published,24,26,29–31 including comparisons between
two common commercial MS platforms.32 On the
other hand, a large number of the applications of
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nuclear magnetic resonance (NMR) spectroscopy in
metabolomics have been spectroscopy-based chemometric
approaches.5,33 Multiple highly implausible conclusions,
for example in relation to coronary heart disease and
cancer diagnostics, have been published.3,7 However, dur-
ing the past 20 years NMR-based lipoprotein subclass
profiling has been commercialized and become visible in
epidemiology and clinical applications.34,35 NMR spec-
troscopy can also be used as a general method to quantify
multiple molecular constituents in serum and in other bio-
fluids.6,28,36–38 However, few applications apart from
focused lipoprotein profiling,35,39 have been published in
epidemiological contexts: only one quantitative serum
metabolomics platform being systematically applied in
metabolic profiling studies of more than a thousand peo-
ple.6,28,40 The pros and cons of NMR and MS for meta-
bolic profiling have been extensively covered in multiple
reviews.2,6,41–44 MS-based lipidomics in epidemiology is
reviewed in this issue by Meikle and co-workers,45 with
the anticipation that further progress is in sight from large,
well-characterized cohorts. In addition, a compelling re-
minder of the current possibilities of in vivo metabolic phe-
notyping, and a vision of how to reach large-scale
neurochemical profiling in epidemiological research, is
provided in this issue by McKay and Tkac.46
Combining MS and NMR and notes on
replication and causality
So far only a few epidemiological studies have combined
MS and NMR methodologies. These are important for
increasing the number of metabolic measures studied and
also to validate biomarker findings by different technolo-
gies. Recently Wahl and colleagues47 combined over 400
quantitative measures from serum MS and NMR platforms
for over 1600 participants, when studying a multi-omic
signature of body weight change in a population-based co-
hort. Wu¨rtz and colleagues15 corroborated NMR-based
cardiovascular biomarker associations with MS in two
population cohorts with 671 and 2289 individuals. In this
issue, Vogt and coauthors48 characterize associations be-
tween serum 25-hydroxyvitamin D concentrations and
those of 415 metabolite and lipid measures, quantified by
both NMR- and MS-based platforms in 1726 people from
a population-based study, KORA F4. Importantly, they
also replicated the majority of their findings in an inde-
pendent population-based study with 6759 individuals for
the NMR-based measures and 609 for the MS-based meas-
ures. In another study in this issue, Nelson and co-work-
ers49 also characterize associations between serum
25-hydroxyvitamin D and serum metabolites, using pri-
marily a non-targeted MS-based approach with eventually
940 compounds identified in eight mutually exclusive
chemical classes; lipids, amino acids, xenobiotics, peptides,
co-factors and vitamins, carbohydrates, energy metabolites
and nucleotides. This is a remarkable metabolic coverage
from a technical point of view. Nevertheless, the results are
weakened by the lack of replication. Comparison of the re-
sults from Nelson and co-workers49 with those of Vogt
and coauthors48 illustrates the importance of biologically
independent data; for example, the association of 3-car-
boxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF)
with 25-hydroxyvitamin D is similarly positive and strong
in all three cohorts; however, eicosapentaenoate (EPA) and
docosahexaenoate (DHA), which show strong positive
associations in the ATBC study,49 do not associate with
25-hydroxyvitamin D in KORA F4.48 Possible explanation
for this discrepancy is the finding in the ATBC study that
retinol influenced the associations between 25-hydroxyvi-
tamin D and EPA as well as DHA.49
There are of course many possible confounding factors
that complicate interpretations of cross-sectional epi-
demiological studies, particularly when aiming to infer
causality,22 which Mendelian randomization analyses can
attempt to circumvent. A recently published study, apply-
ing the Mendelian randomization framework50–53 to inves-
tigate potential causality in the association between
25-hydroxyvitamin D and schizophrenia, gives an exem-
plar of how, in certain cases, potential confounding by life-
style factors can be minimized.54 The study findings
suggested that associations between schizophrenia and
25-hydroxyvitamin D may not be causal, and, therefore
the evidential basis for vitamin D supplementation as a
candidate approach for preventing schizophrenia is weak-
ened. Similarly, a recent extensive Mendelian randomiza-
tion study provides no support for a causal role for
25-hydroxyvitamin D in the risk of coronary artery dis-
ease.55 On the other hand, in this issue Ong and co-work-
ers56 found that genetically lowered 25-hydroxyvitamin D
levels were associated with higher susceptibility to ovarian
cancer. Along the same lines, genetically lowered
25-hydroxyvitamin D levels have been found to be associ-
ated with increased susceptibility to multiple sclerosis.57
Thus, in relation to these outcomes, vitamin D sufficiency
may be important in delaying onset of or preventing the
disease and might thus merit further investigations in long-
term randomized controlled trials. These recent applica-
tions of the Mendelian randomization framework are
interesting examples of causal epidemiology and a wel-
come reminder that observational association studies, such
as those regarding 25-hydroxyvitamin D and circulating
lipids and metabolites in this issue,48,49 are often prone to
confounding and reverse causation.22 Furthermore, an im-
portant note here is that replication of observational
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associations does not mean causation, as previously illus-
trated in the case of sex hormone-binding globulin and sys-
temic metabolism.58 In relation to these key challenges,
also in this issue, Swerdlow and co-workers59 present im-
portant guidance on how to plan and interpret Mendelian
randomization studies on disease biomarkers: very relevant
in the current era of a wealth of genetic data from genome-
wide studies and the increasing number of quantitative
metabolomics studies in epidemiology.
The use of Mendelian randomization analysis or
randomized controlled trials to assess causality calls for
certain prerequisites to be feasible.53,60,61 One interesting
example in this issue is the study by Wang and co-work-
ers62 on the effects of hormonal contraception on systemic
metabolism. The difficulties in randomizing women to use
hormonal contraception or placebo, and randomizing to
hormonal or non-hormonal contraception, are obvious.
Use of Mendelian randomization analysis to assess the
causal effects of oestrogen and progestin is currently lim-
ited by the lack of genetic variants that are reliable and
consistent proxies for oestrogen and progesterone expos-
ure. Furthermore, even were such variants to be identified,
they might not mimic the effects of taking exogenous hor-
mones. To address these difficulties and strengthen causal
inference Wang et al.62 integrated findings from cross-
sectional and longitudinal study settings. They assessed a
comprehensive molecular profile of 75 metabolic measures
and 37 cytokines in up to 5841 women within three
population-based cohorts. Women using combined oral
contraceptive pills (COCPs) were compared with those
who did not use hormonal contraception. Metabolomics
profiles were also reassessed for 869 women after 6 years
to uncover the metabolic effects of starting, stopping and
persistently using hormonal contraception. The extensive
metabolic measurements allowed multiple novel findings
on the systemic effects of COCPs. Perhaps of greater im-
portance to public health, persistent use of COCPs did
not appear to produce cumulative effects over time and
the metabolic perturbations were reversed upon
discontinuation.62
The study by Wang and co-workers62 applied a quantita-
tive serum NMR metabolomics platform; one that has com-
monly been used in epidemiology and genetics.6,40 The
platform provides some 150 primary concentration meas-
ures. These include a fine-grained lipoprotein subclass
profiling, and quantification of circulating fatty acids,
amino acids, gluconeogenesis-related metabolites and many
other molecules from multiple metabolic pathways, in add-
ition to multiple biomarkers already routinely used in epi-
demiology.15–17,27,28,63–67 The primary measures can also
be used to calculate many derived measures and metabolic
ratios with potential biological importance. In addition to
the study by Wang and co-workers,62 three other papers in
this issue also apply this methodology, namely the above-
mentioned study on serum 25-hydroxyvitamin D by Vogt
and co-authors48 and two by Wu¨rtz and co-workers which
look at metabolic profiling of alcohol consumption68 and
metabolic signatures of birthweight in adulthood.69
Alcohol consumption in nearly 10 000 young adults (in
a cross-sectional setting in three population-based cohorts)
was associated with a complex metabolic signature, com-
prising both favourable and adverse effects in relation to
the risk of cardiovascular disease and type 2 diabetes.68 As
in the study by Wang and co-workers,62 Wu¨rtz et al.68 also
complemented the cross-sectional study setting with a lon-
gitudinal set-up to be able to better assess the potential
causality of the associations. In fact, the metabolic changes
associated with the changes in alcohol intake (during
6-year follow-up in 1466 individuals) matched well with
the cross-sectional results, increasing evidence that these
changes were, at least partly, due to alcohol consumption.
The results of Wu¨rtz et al.68 can be interpreted along the
lines of recent extensive Mendelian randomization ana-
lyses,70 suggesting that reduction of alcohol consumption,
even for light to moderate drinkers, is beneficial for cardio-
vascular health, with the obvious implication that
Mendelian randomization studies of the influence of alco-
hol on the metabolome would be a natural extension of
this work. The study looking at the metabolic signatures of
birthweight in adulthood in 18 288 people is one the larg-
est epidemiological metabolomics studies published to
date.69 These data show that lower birthweight is ad-
versely associated with a wide range of established and
emerging circulating cardiometabolic biomarkers in adult-
hood. However, the magnitudes of metabolic aberrations
were weak (although statistically significant) and the au-
thors questioned their public health relevance.69 The pat-
tern of metabolic deviations associated with lower
birthweight resembled the metabolic signature of higher
adult body mass index (R2 0.77) with 1 kg lower birth-
weight being associated with similar metabolic aberrations
as caused by 0.92 units higher body mass index in adult-
hood. The authors suggested that shared underlying meta-
bolic pathways may be involved and concluded that
birthweight is only a weak indicator of metabolic risk in
adulthood.69
Quantitative molecular data–the base for a
multitude of statistical and
clinical appoaches
When metabolomics gets quantitative,5,6 it no longer mat-
ters if the technology is based on MS or NMR (or whatever
methodology), the output just becomes a list of molecular
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concentrations, the length and details of which depend on
the method in question. This marks a fundamental distinc-
tion from diagnostics-oriented spectroscopy-based chemo-
metric approaches; moving from (potentially thousands of)
spectral data points to (typically up to a few hundred) iden-
tified molecular measures dramatically simplifies the statis-
tical analyses and interpretations of epidemiological data.
Of course, biological and clinical appreciation would need
to be integrated into the metabolomics study rationale to
change the search for non-existent binary disease states in
the case of polygenic outcomes.5,6,9 Although the trans-
formation from spectra to quantitative molecular measures
is a challenge in itself, it is not discussed here since the
topic falls into the domain of analytical chemistry and a
plentiful literature is available.6,34,36,42,71–75 Nevertheless
from the epidemiology perspective, with quantitative
metabolomics data, i.e. with that list of molecular concen-
trations, all is back to basics and business as usual, apart
from the fact that the list of molecular variables is longer
than it has usually been in epidemiological studies. All
standard statistical approaches can be applied in a straight-
forward manner, including adjustments for potential con-
founding factors.6,22,24,25,28 Of course, as with any
quantitative molecular data, the analyses are by no means
limited to standard approaches but, for example, multi-
variate non-linear approaches,76,77 network analyses,77,78
pathway approaches79,80 and integration of multi-omic
data26,47,75,81–86 are all feasible. In fact, this is in contrast
to spectral-based approaches in which these types of ana-
lyses, aiming for detailed biological understanding, would
mostly be impossible to perform and interpret at the mo-
lecular level. Fearnley and Inouye,87 in their review in this
issue, survey epidemiological studies that leverage metabo-
lomics and multi-omics to gain insight into disease mech-
anisms. Whereas they emphasize the role of quantitative
metabolic data in biomarker identification and in under-
standing the metabolic underpinnings of diseases, they also
underline limitations and discuss potential solutions in re-
lation to statistical power issues with respect to sample
sizes and limited coverage of relevant metabolites. They
advocate a conceptual shift from metabolite concentrations
towards experiments and graph-theoretical analyses based
on the reactions themselves, and envision the identification
of subgroups of individuals enriched for variation in rele-
vant subregions of a reaction network in population-level
epidemiological studies.87
In another review in this issue, Sattar and colleagues dis-
cuss the applications and use of metabolomics in cardiome-
tabolic intervention studies and trials.88 They express their
concerns regarding the small scale and focus on surrogate
outcomes in most metabolomics studies in the area.
Advancing a list of recommendations for future biomarker
studies, they call for multi-expertise research coalitions to
work together for rigorous experimental study designs, with
an early focus on truly relevant clinical questions:88 the lat-
ter an issue recently elaborated in relation to clinical re-
search in general by Ioannidis.89 They also present an
interesting and critical discussion on the potential role of
metabolomics in predicting drug responses, and elaborate
this in the case of statins. Their points are well made from
the clinical point of view and very valuable to consider.
Generally, the idea of individual metabolic phenotypes is
alluring90–92 and might in some cases provide additional
and predictive value, for not only drugs but dietary sub-
stances as well.41,93 However this does not necessarily trans-
late into clinical relevance or applicability and, as the review
by Sattar and colleagues88 indicates, applications of metabo-
lomics in clinical trials are scarce. Recently Wu¨rtz and co-
workers published a proof-of-concept study17–a, “natural”,
clinical trial of statin effects94–in which they overcame the
lack of metabolomics data in randomized controlled trials
by using serially collected blood samples in population-
based cohorts, in which a subset of individuals had started
to use statins during follow-up. To verify that the observed
metabolic changes were actually due to the effects of statins,
the analyses were corroborated via Mendelian randomiza-
tion analyses using a genetic variant in the HMGCR gene as
an unconfounded proxy for the pharmacological action of
statins. In fact, this type of combination of metabolomics
data with genetic data in a large number of individuals read-
ily extends to studies of all drugs with established genetic
proxies mimicking their pharmacological action. With
increasing numbers of extensive metabolomics and genetic
data becoming available, we anticipate that comprehensive
metabolic profiles of drug targets are likely to augment drug
development in preclinical stages. Applications of two-
sample Mendelian randomization would allow the gene-risk
factor and gene-outcome associations to be taken from dif-
ferent data sources.95
An early example in drug research is the Consortium
for Metabonomic Toxicology, a collaboration that
involved several pharmaceutical companies in applications
of metabolomics to preclinical drug safety studies; this con-
sortium, via the measurement of a dataset of NMR spectra
of rodent urine and serum samples, built a predictive sys-
tem for liver and kidney toxicity.96 However, these
approaches have not been widely adopted by the pharma-
ceutical industry. This reluctance was likely due to the fact
that the methodologies originally used were spectroscopy-
based and chemometrics-driven and thereby not suffi-
ciently sensitive, quantitative, molecular-specific or
platform-independent to permit routine or widespread im-
plementation.97 With the recent shift and developments in
metabolomics towards quantitative molecular
1314 International Journal of Epidemiology, 2016, Vol. 45, No. 5
Downloaded from https://academic.oup.com/ije/article-abstract/45/5/1311/2447874
by University Library user
on 25 July 2018
methodologies,6,32 it may well be worthwhile to revisit this
approach. In biomedical omics applications in general, it is
also worth noting that there have been intensive develop-
ments regarding proteomics methods during the past few
years, and their quantitative applications are likely soon to
become feasible in large-scale studies to complement the
information from other omics domains.98–100
Commercial products and peer-reviewed
publications
Intellectual property rights for most of the quantitative
metabolomics platforms, particularly those applied in most
epidemiological and clinical applications to date, are
owned by companies.6,32 This is not surprising as such,
since innovations are, manifestly, often developed by such
enterprises. Ioannidis has recently reflected upon biomed-
ical innovations and scientific peer review.89,101 He makes
the point that ’stealth research’ is prone to create ambigu-
ity about what evidence can be trusted in a mix of (pos-
sibly) ground-breaking ideas, aggressive corporate
announcements and mass media hype.89 Even more re-
cently, he has called for scientific peer-reviewed articles as
a requirement for technologies aiming to affect health care
at large.101 In this sense–of publishing peer-reviewed scien-
tific articles–the current key metabolomics methodologies
in epidemiology are reasonably represented.6,32 In fact, it
appears that many companies operating in the metabolo-
mics arena have made scientific peer-reviewed articles part
of their business strategy. This is logical in light of the great
potential for commercial benefit provided by independent
technological validation by the scientific community. This
is something that cannot be achieved by patents or intellec-
tual property rights alone; high-quality peer-reviewed pub-
lications are hard to copy or buy. However what still
partly remains, even in the peer-reviewed scientific litera-
ture, is ungrounded hype and expectations of omics sci-
ences transforming not only biological knowledge, but also
medicine and public health.102 In relation to clinical appli-
cations, we should also keep in mind the problematic path-
way from the announcement of new biomarkers to their
integration into predictive and diagnostic models or vali-
dated target identification.18,20,103–107
Is the future for metabolic phenotyping in
epidemiology precarious?
In the history of science and medicine, remarkable leaps in
progress have often been made due to novel physical or
chemical technologies. The new omics methodologies have
already taken a big step, particularly in combination with
genomic data, but also generally in biomedical sciences.
Quantitative molecular technologies have been developed,
many of which are ready for integration into large-scale
epidemiological studies. There is much interest in ‘multio-
mic’ science, in addition to epidemiological and potential
clinical applications. However, considerable hype has also
been generated, often in connection with the concept of
personalized or precision medicine and clinical diagnostic
applications. We suggest that for the future meaningful de-
velopment of metabolic phenotyping in epidemiological
and (potentially) clinical settings, much of the early metab-
olomics literature should be put behind us, just as we
needed to discard a large (and largely meaningless) ‘candi-
date gene’ literature with the arrival of genome-wide asso-
ciation studies.108 We should embrace some of the basic
requirements of good molecular epidemiology: molecular
identification and quantification, large-scale studies, inde-
pendent biological replication of results, and an appreci-
ation of confounding with the aim of understanding
causation. We should combine different metabolomics
methodologies and multiomics combinations to triangulate
findings, explore multiple angles and put findings into a
biological perspective. Furthermore we should apply
appropriate statistical tools (noting caveats related to mul-
tiple testing) and, maybe most importantly, apply
self-critical interpretation of statistical results, biological
implications and potential clinical applicability. Last, we
should carefully reflect–against all the hopes and hypes of
personalized medicine–on the fundamentals of biological
processes in polygenic conditions, and the epidemiological
connotations of this with respect to the articulation of
population and individual perspectives.10,11 As demon-
strated by many excellent contributions in this themed
issue, large-scale metabolic phenotyping, together with
many other omics technologies, are already here to enrich
epidemiology and eventually to make irreversible headway
in the era of systems epidemiology.
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